Zhu Banghao, male, born in May 1963, from Zhujia Village, Hongqi Township, Lintao County. He is a doctor, professor and doctoral supervisor studying in Japan, and the deputy director of the Cardiovascular and Cerebrovascular Research Center of Sun Yat-sen Medical College of Sun Yat-sen University. He is a national new drug review expert, a reviewer of the Journal of Diabetes and Its Complications, and a reviewer of the Chinese Pharmacology Bulletin.
From August 1970 to July 1977, he attended Lingshi School in Lintao County. From August 1977 to July 1979, he attended Hongqi Middle School in Lintao County. From August 1979 to July 1980, he attended Lintao No. 3 Middle School. From September 1980 to July 1985, he studied in the Medical Department of Lanzhou University School of Medicine and obtained a bachelor's degree in medicine. From September 1985 to September 1988, he was a master's student in physiology at lanzhou university school of medicine, engaged in gastrointestinal electrical and motor research, and his research paper won the Excellent Paper Award of the State Education Commission and obtained a master's degree in medicine. From September 1992 to January 1998, he studied in Japan as a trainee of the 11th Seigawa Medical Scholarship, and in December 1997, he was awarded a doctorate in medicine at Showa University. Since March 1998, he has been in the Department of Pharmacology, Sun Yat-sen Medical College, Sun Yat-sen University.
He has published more than thirty papers in domestic and foreign journals, 11 of which are in SCI-cited journals (9 first or corresponding authors). He has presided over more than eight projects, including the National Natural Science Foundation of China, the Key Research Projects of Guangdong Province, the Industry-University-Research Combination Project of the Ministry of Education of Guangdong Province, the Key Projects of the Natural Science Foundation of Guangdong Province, and the Key Breakthrough Projects in Key Fields of Guangdong and Hong Kong. Applied for 3 invention patents, authorized 2, and one was awarded the "National Key Promotion Patent". The national class II new drug (new class 5) with PKC inhibition and Ca2+ blocking effect --- dedicated to the prevention and treatment of diabetic retinopathy was approved for clinical research in 2005, and the approval number: 2005L01419 has now entered the second phase of clinical trials.
(The above information is compiled from the "Lintao No. 3 Middle School Chronicle" and online public information)
Search
![The Ming Dynasty painter Zhu Bang has a mysterious origin and rare works, so why does the British Museum have two paintings[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)